Analysis of Tumor Incidence in Balb/c Mice Used as Controls in Carcinogenicity Experiments

Hepatocarcinogenesis: A Polygenic Model of Inherited Predisposition to Cancer

The murine inbred strain C3H provides an experimental model of inherited predisposition to hepatocellular cancer. Hepatocellular neoplastic lesions induced by chemical carcinogens reach a volume 10-100-fold greater in C3H mice than in genetically resistant strains. However, the huge strain differences in tumor size are explained by relatively small differences (10%-30%) in tumor cell kinetics. Genetic linkage experiments in different crosses demonstrated that six unlinked hepatocarcinogen sensitivity ( Hcs) and two hepatocarcinogen resistance ( Hcr) loci determined quantitative variations in susceptibility to hepatocarcinogenesis. Such results provide the genetic basis for the strain variations in susceptibility to hepatocarcinogenesis and demonstrate a new model of polygenic inheritance of predisposition to cancer.

5-Fluorouracil Carcinogenesis in BALB/c MICE

5-Fluorouracil, a drug mainly used in the treatment of gastrointestinal tract neoplasms, was administered i.p. to BALB/c mice at the dose of 30 mg/kg body weight once a week for 50 weeks to test its carcinogenicity. The treatment induced a significant increase in lung tumor in both sexes (males, p < 0.05; females, p < 0.01) and tumors of the lymphoreticular system in female mice (p < 0.001). These results suggest that 5-fluorouracil is carcinogenic in mice.

Spontaneous and Urethan-Induced Tumor Incidence in B6C3F1 versus B6Cf1 Mice

The incidences of spontaneous tumors of the murine hybrids (C57BL/6J X C3Hf)F1 (B6C3F1) and (C57BL/6J X BALB/c)F1 (B6CF1) were compared in untreated mice kept until 110 weeks of age. Male B6C3F1 and B6CF1 mice had respectively 16% and 20% incidence of lymphomas, 26% and 4% of liver tumors and 12% and 22% of lung tumors. Among B6C3F1 and B6CF1 females, a 36% and 12% incidence of lymphomas, a 6% and zero incidence of liver tumors, and a 4% and 16% of lung tumors were observed. A few other tumors were seen in both hybrids. Groups of male and female mice of the 2 hybrids received 5 i.p. injections of 1000 mg/kg urethan once every other day starting at 10 days of age, and were kept under observation until 65-80 weeks of age. Treated B6C3F1 mice had an earlier mortality than B6CF1 mice due to tumor development. The statistical analysis, allowing for survival, showed a significantly higher lymphoma incidence in male and female B6C3F1 than B6CF1 mice, which had instead a higher incidence of lung tumors. Hepatocellular tumors were seen in both sexes of the 2 hybrids, with a higher frequency in B6C3F1 mice. Male mice of both hybrids had a higher incidence of liver tumors than females.

Carcinogenicity Study of 3-(5-Nitro-2-Furyl)-Imidazo(1,2-α) Pyridine in Mice and Rats

3-(5-nitro-2-furyl)-imidazo(1,2-α)pyridine was tested for carcinogenicity by long-term administration in the diet to CTM mice at 0.1, 0.2 and 0.4 % dose levels and to Wistar rats at 0.2 and 0.4 % dose levels, and by short-term intraperitoneal injections to suckling BALB/c mice. The compound was a strong carcinogen. In CTM mice it induced carcinomas of the esophagus and forestomach at all dose levels and thymic lymphosarcomas at the two highest doses. In male and female rats, esophagus and forestomach papillomas were observed at all dose levels, whereas esophagus and forestomach carcinomas and kidney tumors were observed only at the high dose. In female rats, an increased incidence of mammary tumors was seen at the high dose. The treatment of BALB/c suckling mice by intraperitoneal injections did not induce a clear carcinogenic response.

Pas1 haplotype-dependent genetic predisposition to lung tumorigenesis in rodents: a meta-analysis

Rodent species and strains show wide variations in susceptibility to lung tumorigenesis. In mice, hierarchical clustering of 29 inbred laboratory strains by pulmonary adenoma susceptibility 1 (Pas1) locus polymorphisms separated the strains into either an A/J- or a C57BL/6J-type Pas1 haplotype. A pooled analysis (including >8500 mice) of studies on spontaneous and chemically induced lung tumorigenesis in these strains revealed a significantly higher risk of spontaneous lung tumors [odds ratio (OR) 12.17; 95% confidence interval (CI) 9.00-16.45] as well as of chemically induced lung tumors (OR 15.14; 95% CI 12.51-18.31) in the A/J-type haplotype. Strain differences were observed with six different carcinogens, suggesting that Pas1 locus activity is carcinogen-independent. Thus, the present meta-analysis indicates a link between the genetic control of spontaneous and chemically induced lung tumor susceptibility in mice. The Pas1 susceptibility allele is frequent in the population of inbred mouse strains, whereas a counterpart appears to be absent or rare in rat and hamster strains. These findings might help in the interpretation of results of rodent carcinogenicity bioassays and assessing the risk of lung carcinogenesis from chemicals.

Genetics of liver tumor susceptibility in mice

A good experimental model of genetic predisposition to hepatocellular tumors is the murine strain C3H. These tumors share morphologic similarities with human hepatocellular tumors. After a treatment with a single small dose of chemical carcinogen, the C3H mice show a high susceptibility to the growth of hepatocellular neoplastic lesions, that reach a volume > 100-fold as compared to the corresponding lesions of genetically resistant strains. Genetic linkage analysis experiments were conducted in 2 different crosses, with the C3H as one of the parental strains, and the other parental strains being represented by mice genetically resistant to hepatocarcinogenesis (A/J, M. spretus). Six different regions, on chromosomes 2, 5, 7, 8, 12, and 19 showed a significant linkage with hepatocellular tumor development. These results provide the genetic basis for the strain variations seen in susceptibility to hepatocarcinogenesis, indicating polygenic inheritance of this trait.

Two-stage liver carcinogenesis in the mouse

A two-stage protocol for studying liver carcinogenesis was applied to the mouse. The protocol includes the treatment of 7-day-old mice with a single low dose of an initiating agent (diethylnitrosamine, NDEA), promotion starting after weaning and lasting about 20 weeks, and histologic analysis, at 30 weeks of age, of hepatocellular nodules on H&E stained sections. A stereologic analysis of results allows the evaluation of nodule frequency and size. Using this protocol in B6C3 and B6C mice, we have identified the promoting activity of the phenobarbital-like enzyme inducer, 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP), which was found to be a strong hyperplaseogenic agent for mouse liver. These studies also indicated that the different susceptibility to hepatocarcinogenesis in B6C3 and B6C mice may be related to a higher susceptibility of B6C3 than B6C initiated liver cells to growth stimulation. A long-term study showed that B6C mice have a low incidence of spontaneous liver tumors but are susceptible to chemical hepatocarcinogenesis and, therefore, they may be an alternative model to B6C3 mice in carcinogenesis bioassays.

Carcinogenic activity in mice of diftalone, an anti-inflammatory agent

The anti-inflammatory agent diftalone was administered in the diet to male and female BALB/c mice at 300-, 600-, and 1200-ppm dose levels for 80 weeks, starting at 8 weeks of age. The animals were kept under observation until 126-128 weeks of age, when the experiment was terminated. Diftalone treatment at the highest dose was hepatotoxic and induced hepatocellular tumors in females, angiomas of the liver in males, and angiosarcomas of the liver in male and female mice. The 300- and 600-ppm dose levels were not carcinogenic. The compound was not mutagenic for Salmonella typhimurium.

Carcinogenicity study in mice on pildralazine, a hydralazinelike antihypertensive compound

Pildralazine, a hydralazinelike antihypertensive vasodilator containing a free hydrazine group, was administered in the drinking water to male and female B6C3F1 and to female BALB/c mice at 100, 200, and 400 ppm dose levels for 80 weeks. The animals were kept under observation until 130-133 weeks of age, when the experiment was terminated. A transplacental-infantile bioassay was also carried out with pildralazine administered in the drinking water at 200 and 400 ppm dose levels to female C57BL/6J mice for 1 week before mating with C3Hf males and during mating and pregnancy. The progeny received the same doses for 10 weeks after birth and were kept under observation until 80-85 weeks of age, when the experiment was terminated. In both long-term and transplacental-infantile assays, control and treated groups developed the pattern of tumors usually observed in the strains used and no tumor type at any site appeared to be related to treatment.

Comparison of urethane-induced sister-chromatid exchanges in various murine strains, and the effect of enzyme inducers

The induction of sister-chromatid exchanges (SCEs) by urethane, 150 and 300 mg/kg administered i.p., was examined in bone-marrow cells of AKR, BALB/c, C3Hf, C57BL/6J and DBA/2 male mice. In all strains, the base-line level of SCE/cell was similar, ranging from 4.3 to 8.7, and the response increased with the dose of urethane. DBA/2 mice were the most susceptible to urethane at both dose levels, with 30.6 SCE/cell after treatment with 300 mg/kg, whereas the response of the other strains was from 17.4 to 21.5 SCE/cell at the same urethane dose. Pretreatment of C57BL/6J and DBA/2 mice with phenobarbital decreased the SCE frequencies induced by urethane, 300 mg/kg, to 70%, whereas a prior administration of beta-naphthoflavone reduced SCE levels in C57BL/6J but not in DBA/2 mice.

Lack of Oncogenic Activity of Doxorubicin and Daunorubicin in BALB/c Mice

The oncogenic activity of doxorubicin and daunorubicin, given i.v. once at the dose of 5 and 10 mg/kg, respectively, to male and female BALB/c mice, was examined. Compared with controls treated with a saline solution, about 1 year after administration, no significant statistical differences was noted in tumor incidence. The data obtained differ greatly from the considerable oncogenic power demonstrated by the 2 drugs with regards to rats.

Lack of carcinogenicity in mice of 4,4-'diaminobenzanilide and 4,4'-diaminoazobenzene, two intermediates used in the manufacture of azo dyes

4,4'-Diaminobenzanilide and 4,4'-diaminoazobenzene were administered in the diet to BALB/c mice at 100, 300 and 600 ppm dose levels for 60 weeks. The animals were kept under observation until 140 weeks of age when the experiment was terminated. Control and treated groups developed the pattern of tumours usually observed in BALB/c mice. No tumour type at any site was related to treatment.